Dr Hans Lennernäs, a Professor of Biopharmaceutics at Uppsala University in Sweden, has joined Recipharm Pharmaceutical Development’s Board of Directors.
Lennernäs currently manages an IMI project with a budget of €24.5m entitled OrBiTo, which aims to improve oral drug delivery.
His research is focused on membrane transport and metabolism of drugs/metabolites in the gastrointestinal tract, hepatobiliary system and cancer tissues.
Lennernäs has served as Principal Investigator in an extensive collaboration with the US Food Drug & Administration, the University of Michigan, US, and the Medical Product Agency, Sweden over several years in which he developed a new guideline for the Biopharmaceutics Classification System. He has established an extensive and widely used human permeability database.
In addition to his academic achievements, Lennernäs has co-founded several companies including DuoCort Pharma, and LIDDS, while investing in a number of patents.
